{
  "guideline": {
    "id": "PA166104807",
    "name": "Annotation of FDA Label for fluorouracil and DPYD",
    "objCls": "Label Annotation",
    "source": "FDA",
    "version": 31,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166104807",
    "relatedChemicals": [
      {
        "id": "PA128406956",
        "name": "fluorouracil",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA145",
        "name": "dihydropyrimidine dehydrogenase",
        "symbol": "DPYD"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166310742",
      "name": "Recommendation Annotation PA166310742",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA128406956",
          "name": "fluorouracil",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452213181,
        "html": "<p>&quot;Increased Risk of Serious or Fatal Adverse Reactions in Patients with Low or Absent Dipyrimidine Dehydrogenase (DPD) Activity...Based on postmarketing reports, patients with certain homozygous or certain compound heterozygous mutations in the DPD gene that result in complete or near complete absence of DPD activity are at increased risk for acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by fluorouracil (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity). Patients with partial DPD activity may also have increased risk of severe, life-threatening, or fatal adverse reactions caused by fluorouracil...Withhold or permanently discontinue fluorouracil based on clinical assessment of the onset, duration and severity of the observed toxicities in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity. No fluorouracil dose has been proven safe for patients with complete absence of DPD activity. There is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by any specific test.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "DPYD": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166310743",
      "name": "Recommendation Annotation PA166310743",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA128406956",
          "name": "fluorouracil",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452213182,
        "html": "<p>&quot;Increased Risk of Serious or Fatal Adverse Reactions in Patients with Low or Absent Dipyrimidine Dehydrogenase (DPD) Activity...Based on postmarketing reports, patients with certain homozygous or certain compound heterozygous mutations in the DPD gene that result in complete or near complete absence of DPD activity are at increased risk for acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by fluorouracil (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity). Patients with partial DPD activity may also have increased risk of severe, life-threatening, or fatal adverse reactions caused by fluorouracil...Withhold or permanently discontinue fluorouracil based on clinical assessment of the onset, duration and severity of the observed toxicities in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity. No fluorouracil dose has been proven safe for patients with complete absence of DPD activity. There is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by any specific test.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "DPYD": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Carac (fluorouracil), NDA020985, Valeant Pharmaceuticals North America LLC",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020985"
    },
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Fluoroplex (fluorouracil), NDA016988, Aqua Pharmaceuticals, LLC",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016988"
    },
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product fluorouracil (NDA012209)",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=012209"
    }
  ],
  "version": "2024-03-08-14-34"
}